Article

Temozolomide – what regimen in what situation?

memo - Magazine of European Medical Oncology 04/2012; 2:8-9. DOI:10.1007/s12254-009-0127-5 pp.8-9

ABSTRACT Temozolomide (Temodal®) an alkylating oral cytotoxic drug, has significantly improved overall survival of patients suffering from malignant brain
tumours and has brought new initiative into the treatment of these tumours. Whereas Temozolomide (TMZ) is approved for the
treatment of first-line glioblastoma and the relapse of glioblastoma and anaplastic glioma and is compassionately used in
other settings including the first-line therapy of anaplastic glioma and low-grade gliomas and the relapse of low-grade gliomas,
medulloblastomas/PNETs and primary CNS-lymphomas are frequently treated with TMZ in a compassionate setting, especially if
they relapse. The various entities are currently undergoing different regimens. These will be discussed in detail.

0 0
 · 
0 Bookmarks
 · 
23 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

alkylating oral cytotoxic drug
 
anaplastic glioma
 
compassionate
 
compassionately
 
first-line glioblastoma
 
first-line therapy
 
low-grade gliomas
 
new initiative
 
settings
 
Temodal®
 
Temozolomide
 
TMZ
 
various entities